Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial
- 1 July 1991
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapyJournal of Immunological Methods, 1990
- The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanomaCancer, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in manThe American Journal of Medicine, 1987
- Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced CancerAnnals of Internal Medicine, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated CancerJAMA, 1986
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.Proceedings of the National Academy of Sciences, 1985
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958